Matt Galsky, MD discusses several abstracts presented at the 2023 ASCO GU Cancers Symposium on perioperative nivolumab for urothelial cancer, including an update on the CheckMate 274 trial that examined adjuvant nivolumab versus placebo in patients with high-risk muscle invasive urothelial cancer after radical surgery. Dr. Galsky is the Director of Genitourinary Medical Oncology at The Tisch Cancer Institute and Professor of Medicine at the Icahn School of Medicine at Mount Sinai.